In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Ceribell, Inc., with a price target of $30.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marie Thibault has given his Buy rating due to a combination of factors including Ceribell’s strong Q4 performance and favorable outlook for 2026. The company delivered revenue growth ahead of expectations, driven by higher product sales, better-than-modeled utilization, and disciplined operating expenses that led to a narrower loss per share, while also maintaining robust gross margins.
Looking ahead, management’s guidance implies solid double-digit growth, with expanding account penetration, increasing productivity of the sales force, and new initiatives in VA hospitals, pediatrics, neonates, and delirium monitoring providing multiple avenues for upside. Thibault also views the company’s cash position and path to cash flow breakeven, combined with a valuation anchored in a 7x EV/Sales multiple and the potential to outperform current sales guidance, as supportive of a Buy recommendation.